Superworth

Kodiak Sciences EPS KOD

Diluted earnings per share by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
−$4.19
Latest quarter, Q2 FY26
−$1.05
Fiscal year 2025
−$4.32

Kodiak Sciences' earnings per share was −$4.19 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$1.05.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$4.32n/a
FY2024−$3.36n/a
FY2023−$4.96n/a
FY2022−$6.39n/a
FY2021−$2.46n/a
FY2020−$0.58n/a
FY2019−$0.25n/a
FY2018−$0.77n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$1.05n/a−$4.19
Q1 FY26−$0.94n/a−$4.17
Q4 FY25−$1.04n/a−$4.32
Q3 FY25−$1.16n/a−$4.12
Q2 FY25−$1.03n/a−$3.80
Q1 FY25−$1.09n/a−$3.63
Q4 FY24−$0.84n/a−$3.36
Q3 FY24−$0.84n/a−$3.65
Q2 FY24−$0.86n/a−$3.76
Q1 FY24−$0.82n/a−$4.43
Q4 FY23−$1.13n/a−$4.96
Q3 FY23−$0.95n/a−$5.18

Against its peers

Companies in Biotechnology nearest Kodiak Sciences' size, closest first, today.

CompanyEPS, 12 monthsGrowth
KODKodiak Sciences−$4.19
KRYSKrystal Biotech$7.98+62% a year
RGENRepligen$0.73
TECHBIO-TECHNE$1.15+150% a year
ADMAAdma Biologics$0.70−18% a year
VCELVericel$0.46+283% a year
HALOHalozyme Therapeutics$3.35−23% a year
NBIXNeurocrine Biosciences$6.82+102% a year
EXELExelixis$3.18+53% a year
INCYIncyte$7.85+78% a year
UTHRUnited Therapeutics$27.95+9% a year
Peer median$3.27

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Kodiak Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.